Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by WILLIAM H MORRISON and DAVID ROSENTHAL.
WILLIAM H MORRISON
Connection Strength
6.876
DAVID ROSENTHAL
  1. Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2021 06; 159:21-27.
    View in: PubMed
    Score: 0.193
  2. Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma. Head Neck. 2020 10; 42(10):2791-2800.
    View in: PubMed
    Score: 0.182
  3. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22.
    View in: PubMed
    Score: 0.174
  4. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
    View in: PubMed
    Score: 0.167
  5. Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope. 2020 01; 130(1):146-153.
    View in: PubMed
    Score: 0.167
  6. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8.
    View in: PubMed
    Score: 0.155
  7. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck?Cancer. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1002-1011.
    View in: PubMed
    Score: 0.149
  8. Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 07 01; 98(3):532-540.
    View in: PubMed
    Score: 0.143
  9. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016 12; 38(12):1739-1751.
    View in: PubMed
    Score: 0.140
  10. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016 Jun 01; 2(6):782-9.
    View in: PubMed
    Score: 0.138
  11. Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiother Oncol. 2015 Oct; 117(1):132-8.
    View in: PubMed
    Score: 0.132
  12. Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E452-8.
    View in: PubMed
    Score: 0.130
  13. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15; 121(10):1608-19.
    View in: PubMed
    Score: 0.126
  14. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014 Jul 01; 120(13):1975-84.
    View in: PubMed
    Score: 0.119
  15. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7.
    View in: PubMed
    Score: 0.107
  16. Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):204-9.
    View in: PubMed
    Score: 0.100
  17. Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):455-61.
    View in: PubMed
    Score: 0.086
  18. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):747-55.
    View in: PubMed
    Score: 0.079
  19. Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck. 2006 Nov; 28(11):967-73.
    View in: PubMed
    Score: 0.071
  20. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 01; 101(11):2567-73.
    View in: PubMed
    Score: 0.062
  21. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol. 2024 Nov 01; 202:110602.
    View in: PubMed
    Score: 0.062
  22. Detection of Alteration in Carotid Artery Volumetry Using Standard-of-care Computed Tomography Surveillance Scans Following Unilateral Radiation Therapy for Early-stage Tonsillar Squamous Cell Carcinoma Survivors: A Cross-Sectional Internally-Matched Carotid Isodose Analysis. medRxiv. 2024 May 16.
    View in: PubMed
    Score: 0.060
  23. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Phys Imaging Radiat Oncol. 2024 Jan; 29:100540.
    View in: PubMed
    Score: 0.059
  24. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer. 2003 Dec 01; 98(11):2322-8.
    View in: PubMed
    Score: 0.058
  25. Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation. Clin Transl Radiat Oncol. 2024 Jan; 44:100700.
    View in: PubMed
    Score: 0.058
  26. Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio. Cancers (Basel). 2023 Aug 29; 15(17).
    View in: PubMed
    Score: 0.057
  27. Temporal characterization of acute pain and toxicity kinetics during radiation therapy for head and neck cancer. A retrospective study. Oral Oncol Rep. 2023 Sep; 7.
    View in: PubMed
    Score: 0.057
  28. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Curr Oncol. 2022 08 31; 29(9):6303-6313.
    View in: PubMed
    Score: 0.053
  29. Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):1054-1062.
    View in: PubMed
    Score: 0.052
  30. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.052
  31. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. AMIA Annu Symp Proc. 2021; 2021:979-988.
    View in: PubMed
    Score: 0.051
  32. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol. 2022 Jan; 32:35-40.
    View in: PubMed
    Score: 0.050
  33. Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clin Transl Radiat Oncol. 2021 Sep; 30:78-83.
    View in: PubMed
    Score: 0.050
  34. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021 11; 43(11):3331-3344.
    View in: PubMed
    Score: 0.049
  35. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.049
  36. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther. 2021; 8(1):108-118.
    View in: PubMed
    Score: 0.049
  37. Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther. 2021; 8(1):213-222.
    View in: PubMed
    Score: 0.049
  38. Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther. 2021; 8(1):234-247.
    View in: PubMed
    Score: 0.049
  39. Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. Int J Part Ther. 2021; 8(1):319-327.
    View in: PubMed
    Score: 0.049
  40. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Curr Treat Options Oncol. 2021 06 04; 22(6):54.
    View in: PubMed
    Score: 0.049
  41. Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125.
    View in: PubMed
    Score: 0.047
  42. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
    View in: PubMed
    Score: 0.047
  43. Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. J Appl Clin Med Phys. 2021 Jan; 22(1):37-44.
    View in: PubMed
    Score: 0.047
  44. Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer. 2020 Sep 23; 20(1):912.
    View in: PubMed
    Score: 0.047
  45. A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1359-1363.
    View in: PubMed
    Score: 0.046
  46. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
    View in: PubMed
    Score: 0.046
  47. Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiother Oncol. 2020 10; 151:119-125.
    View in: PubMed
    Score: 0.046
  48. Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
    View in: PubMed
    Score: 0.045
  49. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):929-935.
    View in: PubMed
    Score: 0.045
  50. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139.
    View in: PubMed
    Score: 0.045
  51. A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncol. 2020 07; 106:104665.
    View in: PubMed
    Score: 0.045
  52. SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):363-371.
    View in: PubMed
    Score: 0.045
  53. Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck. 2020 08; 42(8):2137-2144.
    View in: PubMed
    Score: 0.045
  54. Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time? Clin Transl Radiat Oncol. 2020 May; 22:98-105.
    View in: PubMed
    Score: 0.045
  55. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020 08; 42(8):1939-1953.
    View in: PubMed
    Score: 0.045
  56. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
    View in: PubMed
    Score: 0.044
  57. Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer. 2020 02 15; 126(4):749-756.
    View in: PubMed
    Score: 0.044
  58. Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):185-193.
    View in: PubMed
    Score: 0.044
  59. Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiat Oncol. 2019 Aug 19; 14(1):148.
    View in: PubMed
    Score: 0.043
  60. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
    View in: PubMed
    Score: 0.043
  61. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
    View in: PubMed
    Score: 0.043
  62. Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
    View in: PubMed
    Score: 0.043
  63. Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Phys Imaging Radiat Oncol. 2019 Apr; 10:29-34.
    View in: PubMed
    Score: 0.042
  64. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
    View in: PubMed
    Score: 0.042
  65. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019 05 01; 125(9):1536-1546.
    View in: PubMed
    Score: 0.041
  66. Author Correction: Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018 11 27; 5(1):1.
    View in: PubMed
    Score: 0.041
  67. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. Oral Oncol. 2019 01; 88:66-74.
    View in: PubMed
    Score: 0.041
  68. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903.
    View in: PubMed
    Score: 0.041
  69. Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018 09 04; 5:180173.
    View in: PubMed
    Score: 0.040
  70. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.
    View in: PubMed
    Score: 0.040
  71. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 09; 40(9):2060-2069.
    View in: PubMed
    Score: 0.040
  72. Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. J Neurosurg. 2019 03 01; 130(3):812-821.
    View in: PubMed
    Score: 0.039
  73. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
    View in: PubMed
    Score: 0.039
  74. Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiother Oncol. 2018 01; 126(1):75-80.
    View in: PubMed
    Score: 0.038
  75. Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
    View in: PubMed
    Score: 0.038
  76. Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clin Transl Radiat Oncol. 2017 Dec; 7:28-35.
    View in: PubMed
    Score: 0.038
  77. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
    View in: PubMed
    Score: 0.038
  78. Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiat Oncol. 2017 Aug 15; 12(1):129.
    View in: PubMed
    Score: 0.038
  79. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056.
    View in: PubMed
    Score: 0.037
  80. Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017 10; 39(10):2079-2087.
    View in: PubMed
    Score: 0.037
  81. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol. 2017 09; 72:90-97.
    View in: PubMed
    Score: 0.037
  82. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
    View in: PubMed
    Score: 0.037
  83. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017 05 01; 123(9):1653-1661.
    View in: PubMed
    Score: 0.036
  84. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
    View in: PubMed
    Score: 0.036
  85. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 2016 11 15; 122(21):3411-3412.
    View in: PubMed
    Score: 0.035
  86. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol. 2016 07; 120(1):48-55.
    View in: PubMed
    Score: 0.035
  87. Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):30-41.
    View in: PubMed
    Score: 0.034
  88. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
    View in: PubMed
    Score: 0.034
  89. Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. Int J Part Ther. 2016 Mar; 2(4):533-543.
    View in: PubMed
    Score: 0.034
  90. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1117-31.
    View in: PubMed
    Score: 0.034
  91. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head Neck. 2016 04; 38 Suppl 1:E2091-9.
    View in: PubMed
    Score: 0.034
  92. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1107-14.
    View in: PubMed
    Score: 0.034
  93. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.034
  94. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
    View in: PubMed
    Score: 0.033
  95. Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head Neck. 2016 04; 38 Suppl 1:E1459-66.
    View in: PubMed
    Score: 0.033
  96. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head Neck. 2016 04; 38 Suppl 1:E1472-80.
    View in: PubMed
    Score: 0.033
  97. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):241-247.
    View in: PubMed
    Score: 0.033
  98. A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):344-352.
    View in: PubMed
    Score: 0.033
  99. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E925-33.
    View in: PubMed
    Score: 0.033
  100. Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. Head Neck. 2016 04; 38 Suppl 1:E580-7.
    View in: PubMed
    Score: 0.032
  101. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral Oncol. 2015 Feb; 51(2):195-201.
    View in: PubMed
    Score: 0.031
  102. Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiother Oncol. 2014 Sep; 112(3):321-5.
    View in: PubMed
    Score: 0.031
  103. Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg. 2014 Oct; 151(4):619-26.
    View in: PubMed
    Score: 0.030
  104. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014 Oct 01; 120(19):3082-8.
    View in: PubMed
    Score: 0.030
  105. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol. 2014 May; 111(2):281-8.
    View in: PubMed
    Score: 0.030
  106. Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. Head Neck. 2014 Jun; 36(6):819-25.
    View in: PubMed
    Score: 0.029
  107. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013 Sep 01; 119(17):3162-9.
    View in: PubMed
    Score: 0.028
  108. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.027
  109. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
    View in: PubMed
    Score: 0.026
  110. Sonographic examination of the neck after definitive radiotherapy for node-positive oropharyngeal cancer. AJNR Am J Neuroradiol. 2011 Sep; 32(8):1532-8.
    View in: PubMed
    Score: 0.025
  111. Outcomes of malignant tumors of the lacrimal apparatus: the University of Texas MD Anderson Cancer Center experience. Cancer. 2011 Jun 15; 117(12):2801-10.
    View in: PubMed
    Score: 0.024
  112. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck. 2010 Jul; 32(7):829-36.
    View in: PubMed
    Score: 0.023
  113. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1356-65.
    View in: PubMed
    Score: 0.023
  114. Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head Neck. 2010 Apr; 32(4):473-80.
    View in: PubMed
    Score: 0.023
  115. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10.
    View in: PubMed
    Score: 0.022
  116. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74.
    View in: PubMed
    Score: 0.022
  117. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009 Aug; 31(8):1031-8.
    View in: PubMed
    Score: 0.022
  118. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15.
    View in: PubMed
    Score: 0.021
  119. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1083-91.
    View in: PubMed
    Score: 0.021
  120. Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthalmic Plast Reconstr Surg. 2008 Nov-Dec; 24(6):444-9.
    View in: PubMed
    Score: 0.020
  121. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck. 2008 Jul; 30(7):883-8.
    View in: PubMed
    Score: 0.020
  122. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.020
  123. Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):916-25.
    View in: PubMed
    Score: 0.020
  124. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer. 2008 Jan 01; 112(1):111-8.
    View in: PubMed
    Score: 0.019
  125. Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? Int J Radiat Oncol Biol Phys. 2007 Nov 15; 69(4):1290-6.
    View in: PubMed
    Score: 0.019
  126. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):719-30.
    View in: PubMed
    Score: 0.019
  127. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):438-44.
    View in: PubMed
    Score: 0.018
  128. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):445-52.
    View in: PubMed
    Score: 0.018
  129. Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):469-76.
    View in: PubMed
    Score: 0.017
  130. Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. Cancer. 2006 May 01; 106(9):1950-7.
    View in: PubMed
    Score: 0.017
  131. Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Apr 01; 64(5):1559-69.
    View in: PubMed
    Score: 0.017
  132. Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):678-83.
    View in: PubMed
    Score: 0.017
  133. Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005 Mar; 7(2):131-6.
    View in: PubMed
    Score: 0.016
  134. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.015
  135. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):960-70.
    View in: PubMed
    Score: 0.015
  136. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):743-51.
    View in: PubMed
    Score: 0.015
  137. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol. 2004 Apr; 14(2):103-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.